In conclusion, we constructed and validated a novel PECAR score predicting the recurrence of HBV-related CHC patients in stage I/II. The PECAR score may help predict the per-patient recurrence risk and facilitate clinicians manage patients with stage I/II CHC patients, and further studies are also needed to improve clinical strategy.

Abbreviations list

Continue Reading

CHC, combined hepatocellular cholangiocarcinoma; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; OS, overall survival; DFS, disease-free survival; BCLC, Barcelona Clinic Liver Cancer; HKLC, Hong Kong Liver Cancer; AJCC, American Joint Committee on Cancer; LCSGJ, Liver Cancer Study Group of Japan; HBV, hepatitis B virus; MRI, magnetic resonance imaging; CT, computed tomography; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; PEI, percutaneous ethanol injection; C-index, concordance index; VI, vascular invasion.


We all express our sincere thanks to Zun-Song Hu for statistical analysis. We would like to thank the participants and staff of the Zhongshan Hospital for their valuable contributions; the staff included Zhen-Bin Ding, Yuan-Fei Peng, Zhi Dai, and Pei-Yun Zhou. This work was supported by grants from the National Natural Science Foundation of China (81472674, 81773067, 81800790 and 81502486), the National Key Sci-Tech Project (2012ZX10002011-002), the Shanghai Committee of Science and Technology, China (No. 16JC1404000), the Shu Guang Project of Shanghai Municipal Education Commission and Shanghai Education Development Foundation (13SG04), and the China Postdoctoral Science Foundation Funded Project (2018M640343).


The authors declared no conflicts of interest in this work.

Meng-Xin Tian,1,2,* Liu-Ping Luo,3,4,* Wei-Ren Liu,1,2,* Wei Deng,5 Jia-Cheng Yin,1,2 Lei Jin,1,2 Xi-Fei Jiang,1,2 Yu-Fu Zhou,1,2 Wei-Feng Qu,1,2 Zheng Tang,1,2 Han Wang,1,2 Chen-Yang Tao,1,2 Yuan Fang,1,2Shuang-Jian Qiu,1,2 Jian Zhou,1–2,6 Jing-Feng Liu,3,4 Jia Fan,1–2,6 Ying-Hong Shi1,2

1Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, People’s Republic of China; 3Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 4The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, People’s Republic of China; 5Department of Health Statistics and Social Medicine, Key Laboratory of Public Health Safety, Ministry of Education, School of Public Health, Fudan University, Shanghai, People‘s Republic of China; 6Institutes of Biomedical Sciences, Fudan University, Shanghai, People‘s Republic of China


1. Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–629. doi:10.1245/s10434-008-0278-3

2. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25(4):647–655.

3. Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94(7):2040–2046.

4. Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol. 2012;19(9):2869–2876. doi:10.1245/s10434-012-2328-0

5. Lee SD, Park SJ, Han SS, et al. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Hepatobiliary Pancreatic Dis Int. 2014;13(6):594–601. doi:10.1016/S1499-3872(14)60275-7

6. Brunt E, Aishima S, Clavien PA, et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology (Baltimore, Md). 2018;68:113–126. doi:10.1002/hep.29789

7. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-1007122

8. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–1700.e1693. doi:10.1053/j.gastro.2014.02.032

9. Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2011;117(10):2170–2177. doi:10.1002/cncr.25712

10. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16(1):14–22. doi:10.1245/s10434-008-0180-z

11. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg. 2003;10(4):288–291. doi:10.1007/s00534-002-0732-8

12. Tian MX, He WJ, Liu WR, et al. A novel risk prediction model for patients with combined hepatocellular-cholangiocarcinoma. J Cancer. 2018;9(6):1025–1032. doi:10.7150/jca.23229

13. Tao CY, Liu WR, Jin L, et al. Surgical treatment of combined hepatocellular-cholangiocarcinoma is as effective in elderly patients as it is in younger patients: a propensity score matching analysis. J Cancer. 2018;9(6):1106–1112. doi:10.7150/jca.23921

14. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol. 2004;41(2):292–298. doi:10.1016/j.jhep.2004.04.030

15. Hurlimann J, Gardiol D. Immunohistochemistry in the differential diagnosis of liver carcinomas. Am J Surg Pathol. 1991;15(3):280–288.

16. Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg (Chicago, Ill: 1960). 2003;138(1):86–90.

17. Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018;24(9):2074–2081. doi:10.1158/1078-0432.CCR-17-2899

18. European Association for the Study of the Liver. Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019

19. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. doi:10.1016/j.jhep.2014.01.021

20. Aoki K, Takayasu K, Kawano T, et al. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology (Baltimore, Md). 1993;18(5):1090–1095.

21. Sullivan LM, Massaro JM, D‘Agostino RB Sr. Presentation of multivariate data for clinical use: the framingham study risk score functions. Stat Med. 2004;23(10):1631–1660. doi:10.1002/sim.1742

22. Brentnall AR, Cuzick J. Use of the concordance index for predictors of censored survival data. Stat Methods Med Res. 2018;27(8):2359–2373. doi:10.1177/0962280216680245

23. Pencina MJ, Steyerberg EW, D‘Agostino RB Sr. Net reclassification index at event rate: properties and relationships. Stat Med. 2017;36(28):4455–4467. doi:10.1002/sim.7041

24. Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology. 2014;25(1):114–121. doi:10.1097/EDE.0000000000000018

25. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189(1):120–125. doi:10.1016/j.amjsurg.2004.03.018

26. Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25(9):1485–1492. doi:10.1111/j.1440-1746.2010.06430.x

27. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant. 2011;17(8):934–942. doi:10.1002/lt.22307

28. Cai X, Zhai J, Kaplan DE, et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology (Baltimore, Md). 2012;56(5):1804–1816. doi:10.1002/hep.25874

29. Ariizumi S, Kotera Y, Katagiri S, Nakano M, Yamamoto M. Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor. Ann Surg Oncol. 2012;19(5):1628–1636. doi:10.1245/s10434-011-2150-0

30. Shin CI, Lee JM, Kim SH, et al. Recurrence patterns of combined hepatocellular-cholangiocarcinoma on enhanced computed tomography. J Comput Assist Tomogr. 2007;31(1):109–115. doi:10.1097/01.rct.0000235072.34808.9b

31. Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 2013;37(4):496–505. doi:10.1097/PAS.0b013e31827332b0

32. Shibahara J, Hayashi A, Misumi K, et al. Clinicopathologic characteristics of hepatocellular carcinoma with reactive ductule-like components, a subset of liver cancer currently classified as combined hepatocellular-cholangiocarcinoma with stem-cell features, typical subtype. Am J Surg Pathol. 2016;40:608–616. doi:10.1097/PAS.0000000000000579

33. Mok Y, Son DK, Yun YD, Jee SH, Samet JM. gamma-glutamyltransferase and cancer risk: the Korean cancer prevention study. Int J Cancer J Int Du Cancer. 2016;138(2):311–319. doi:10.1002/ijc.29659

34. Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261(5):939–946. doi:10.1097/SLA.0000000000000747

35. Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–340. doi:10.1097/SLA.0000000000000236

36. Hyder O, Marques H, Pulitano C, et al. A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg. 2014;149(5):432–438. doi:10.1001/jamasurg.2013.5168

37. Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–1195. doi:10.1200/JCO.2012.41.5984

38. Kim JH, Yoon HK, Ko GY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology. 2010;255(1):270–277. doi:10.1148/radiol.09091076

39. Na SK, Choi GH, Lee HC, et al. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLoS One. 2018;13(6):e0198138. doi:10.1371/journal.pone.0198138

Source: Cancer Management and Research.
Originally published June 5, 2019.

READ FULL ARTICLE Curated publisher From Dovepress